The EVERREST clinical trial is aiming to assess the safety and efficacy of maternal uterine artery injection of an adenovirus containing the Vascular Endothelial Growth Factor transgene (Ad.VEGF), a gene therapy treatment under development to address FGR caused by placental insufficiency [8]. This evidence concerns the gene VEGFA and placental insufficiency.